What are the major opportunities in the Human Metapneumovirus hMPV Therapeutics market? What are the strategies for the Human Metapneumovirus hMPV Therapeutics market?

For detailed insights on the major opportunities and strategies in the Human Metapneumovirus hMPV Therapeutics market, Read More

How does the Human Metapneumovirus hMPV Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Human Metapneumovirus hMPV Therapeutics's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Human Metapneumovirus hMPV Therapeutics market growth? SWOT analysis of the Human Metapneumovirus hMPV Therapeutics market.

For detailed insights on the key dynamics influencing the Human Metapneumovirus hMPV Therapeutics market growth and SWOT analysis of the Human Metapneumovirus hMPV Therapeutics industry, Read More

Human Metapneumovirus (hMPV) Therapeutics Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Human Metapneumovirus (hMPV) Therapeutics Market Report 2026

Name: Human Metapneumovirus (hMPV) Therapeutics Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drug Class (Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-Use (Hospitals And Clinics, Academic And Research Institutions, Other End-Uses) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Human Metapneumovirus (hMPV) Therapeutics Market Overview

• Human Metapneumovirus (hMPV) Therapeutics market size has reached to $0.7 billion in 2025

• Expected to grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 6%

• Growth Driver: Rising Respiratory Infections Fueling Growth of the Human Metapneumovirus (hMPV) Therapeutics Market Due To Increasing Vulnerability Among Key Populations

• Market Trend: Development Of Targeted Antiviral Therapies In The Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Metapneumovirus (hMPV) Therapeutics Market?

Human metapneumovirus (hMPV) therapeutics refers to the medical treatments and interventions aimed at managing and alleviating the symptoms caused by human metapneumovirus, a respiratory virus that commonly affects infants, older people, and immunocompromised individuals. The therapeutics work by inhibiting viral replication, blocking viral entry into host cells, and modulating the immune response to reduce inflammation and disease severity.

The main drug classes for human metapneumovirus (hMPV) therapeutics include antipyretics, decongestants, cough suppressants, and other drug classes. An antipyretic is a substance that reduces fever by lowering the body's temperature through its action on the hypothalamus. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are used across multiple end-use settings such as hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

Human Metapneumovirus (hMPV) Therapeutics Market Global Report 2026 Market Report bar graph

What Is The Human Metapneumovirus (hMPV) Therapeutics Market Size and Share 2026?

The human metapneumovirus (hmpv) therapeutics market size has grown strongly in recent years. It will grow from $0.7 billion in 2025 to $0.74 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to widespread incidence of respiratory viral infections, lack of specific approved antiviral therapies for hmpv, reliance on supportive and symptomatic treatment approaches, increased hospitalization of infants and elderly patients, growing awareness of viral lower respiratory tract infections.

What Is The Human Metapneumovirus (hMPV) Therapeutics Market Growth Forecast?

The human metapneumovirus (hmpv) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to rising focus on developing virus-specific therapeutics, increasing investment in respiratory virus research, growing demand for effective treatments in immunocompromised populations, expansion of clinical trials for novel antiviral agents, increasing preparedness for seasonal respiratory virus outbreaks. Major trends in the forecast period include increasing focus on targeted antiviral therapies for respiratory viruses, rising demand for symptom-based management in pediatric and geriatric patients, growing emphasis on early intervention for high-risk populations, expansion of supportive care therapeutics for viral respiratory infections, increasing clinical research into novel hmpv treatment options.

Book your 30 minutes free consultation with our research experts

Global Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

1) By Drug Class: Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-Use: Hospitals And Clinics, Academic And Research Institutions, Other End-Uses

Subsegments:

1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)

2) By Decongestants: Nasal Decongestants, Oral Decongestants

3) By Cough Suppressants: Dextromethorphan, Benzonatate

4) By Other Drug Classes: Antiviral Agents, Inhaled Corticosteroids

What Is The Driver Of The Human Metapneumovirus (hMPV) Therapeutics Market?

The increasing prevalence of respiratory infections is expected to propel the growth of the human metapneumovirus (HMPV) therapeutics market going forward. Respiratory infections are illnesses that affect the respiratory tract, which includes the nose, throat, airways, and lungs. The increasing number of respiratory infections is due to rising air pollution levels. Pollutants like particulate matter and nitrogen dioxide irritate and weaken the respiratory tract, making individuals more susceptible to infections. Human metapneumovirus (hMPV) therapeutics are essential for treating respiratory infections caused by hMPV by reducing viral replication and inflammation through antiviral treatments and supportive care, ultimately improving health outcomes for vulnerable groups such as infants, the elderly, and immunocompromised patients. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, Australia Chronic Obstructive Pulmonary Disease (COPD), contributed to 3.6% of the total disease burden in 2023. It accounted for 50% of the overall burden from respiratory conditions, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Therefore, the increasing prevalence of respiratory infections drives growth in the human metapneumovirus (HMPV) therapeutics industry.

Key Players In The Global Human Metapneumovirus (hMPV) Therapeutics Market

Major companies operating in the human metapneumovirus (hmpv) therapeutics market are Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.

Global Human Metapneumovirus (hMPV) Therapeutics Market Trends and Insights

Major companies operating in the human metapneumovirus (hMPV) therapeutics market focus on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively combat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-made proteins that mimic the immune system's natural ability to fight diseases. Monoclonal antibodies provide targeted therapy for various diseases, including cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, secured $100 million in Series B financing, led by TCGX with participation from Goldman Sachs Alternatives and others, to advance its next-generation respiratory virus vaccines. The funding supports the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with initial results expected in mid-2025. It will also accelerate the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, to address significant medical burdens in older people.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market?

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax, Inc., for $1.1 billion. With this acquisition, AstraZeneca aims to strengthen its vaccine and respiratory infection portfolio by integrating Icosavax’s innovative virus-like particle (VLP) technology and its potential first-in-class combination vaccine candidate for RSV and hMPV. Icosavax, Inc. is a US-based biopharmaceutical company developing virus-like particle vaccines, including a potential first-in-class combination vaccine for RSV and hMPV.

Regional Outlook

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Metapneumovirus (hMPV) Therapeutics Market?

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Metapneumovirus (hMPV) Therapeutics Market Report 2026?

The human metapneumovirus (hmpv) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus (hmpv) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Human Metapneumovirus (hMPV) Therapeutics Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$0.74 billion
Revenue Forecast In 2035	$0.94 billion
Growth Rate	CAGR of 6.2% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Class, Distribution Channel, End-Use
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Human Metapneumovirus (hMPV) Therapeutics Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Human Metapneumovirus (hMPV) Therapeutics Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Human Metapneumovirus (hMPV) Therapeutics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Human Metapneumovirus (hMPV) Therapeutics Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Focus On Targeted Antiviral Therapies For Respiratory Viruses

4.2.2 Rising Demand For Symptom-Based Management In Pediatric And Geriatric Patients

4.2.3 Growing Emphasis On Early Intervention For High-Risk Populations

4.2.4 Expansion Of Supportive Care Therapeutics For Viral Respiratory Infections

4.2.5 Increasing Clinical Research Into Novel Hmpv Treatment Options

5. Human Metapneumovirus (hMPV) Therapeutics Market Analysis Of End Use Industries

5.1 Hospitals And Clinics

5.2 Pediatric Care Centers

5.3 Geriatric Care Facilities

5.4 Diagnostic And Reference Laboratories

5.5 Academic And Research Institutions

6. Human Metapneumovirus (hMPV) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Human Metapneumovirus (hMPV) Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Human Metapneumovirus (hMPV) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Human Metapneumovirus (hMPV) Therapeutics Market Size, Comparisons And Growth Rate Analysis

7.3. Global Human Metapneumovirus (hMPV) Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Human Metapneumovirus (hMPV) Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Human Metapneumovirus (hMPV) Therapeutics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

9.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes

9.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.3. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals And Clinics, Academic And Research Institutions, Other End-Uses

9.4. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Antipyretic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)

9.5. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Decongestants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Nasal Decongestants, Oral Decongestants

9.6. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Cough Suppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Dextromethorphan, Benzonatate

9.7. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antiviral Agents, Inhaled Corticosteroids

10. Human Metapneumovirus (hMPV) Therapeutics Market Regional And Country Analysis

10.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market

11.1. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Human Metapneumovirus (hMPV) Therapeutics Market

12.1. China Human Metapneumovirus (hMPV) Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Human Metapneumovirus (hMPV) Therapeutics Market

13.1. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Human Metapneumovirus (hMPV) Therapeutics Market

14.1. Japan Human Metapneumovirus (hMPV) Therapeutics Market Overview

14.2. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Human Metapneumovirus (hMPV) Therapeutics Market

15.1. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market

16.1. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Human Metapneumovirus (hMPV) Therapeutics Market

17.1. South Korea Human Metapneumovirus (hMPV) Therapeutics Market Overview

17.2. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Human Metapneumovirus (hMPV) Therapeutics Market

18.1. Taiwan Human Metapneumovirus (hMPV) Therapeutics Market Overview

18.2. Taiwan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Human Metapneumovirus (hMPV) Therapeutics Market

19.1. South East Asia Human Metapneumovirus (hMPV) Therapeutics Market Overview

19.2. South East Asia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market

20.1. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview

20.2. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Human Metapneumovirus (hMPV) Therapeutics Market

21.1. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Human Metapneumovirus (hMPV) Therapeutics Market

22.1. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Human Metapneumovirus (hMPV) Therapeutics Market

23.1. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Human Metapneumovirus (hMPV) Therapeutics Market

24.1. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Human Metapneumovirus (hMPV) Therapeutics Market

25.1. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market

26.1. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview

26.2. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Human Metapneumovirus (hMPV) Therapeutics Market

27.1. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Human Metapneumovirus (hMPV) Therapeutics Market

28.1. North America Human Metapneumovirus (hMPV) Therapeutics Market Overview

28.2. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Human Metapneumovirus (hMPV) Therapeutics Market

29.1. USA Human Metapneumovirus (hMPV) Therapeutics Market Overview

29.2. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Human Metapneumovirus (hMPV) Therapeutics Market

30.1. Canada Human Metapneumovirus (hMPV) Therapeutics Market Overview

30.2. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Human Metapneumovirus (hMPV) Therapeutics Market

31.1. South America Human Metapneumovirus (hMPV) Therapeutics Market Overview

31.2. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Human Metapneumovirus (hMPV) Therapeutics Market

32.1. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Human Metapneumovirus (hMPV) Therapeutics Market

33.1. Middle East Human Metapneumovirus (hMPV) Therapeutics Market Overview

33.2. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Human Metapneumovirus (hMPV) Therapeutics Market

34.1. Africa Human Metapneumovirus (hMPV) Therapeutics Market Overview

34.2. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Segmentation By Distribution Channel, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Human Metapneumovirus (hMPV) Therapeutics Market Regulatory and Investment Landscape

36. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape And Company Profiles

36.1. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Human Metapneumovirus (hMPV) Therapeutics Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Human Metapneumovirus (hMPV) Therapeutics Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

36.3.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Moderna Inc Overview, Products and Services, Strategy and Financial Analysis

37. Human Metapneumovirus (hMPV) Therapeutics Market Other Major And Innovative Companies

Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc.

38. Global Human Metapneumovirus (hMPV) Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market

40. Human Metapneumovirus (hMPV) Therapeutics Market High Potential Countries, Segments and Strategies

40.1 Human Metapneumovirus (hMPV) Therapeutics Market In 2030 - Countries Offering Most New Opportunities

40.2 Human Metapneumovirus (hMPV) Therapeutics Market In 2030 - Segments Offering Most New Opportunities

40.3 Human Metapneumovirus (hMPV) Therapeutics Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Human Metapneumovirus (hMPV) Therapeutics Market, Overview Of Key Products - Product Examples

Table 2: Global Human Metapneumovirus (hMPV) Therapeutics Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Human Metapneumovirus (hMPV) Therapeutics Market, Supply Chain Analysis

Table 4: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Raw Material Providers

Table 5: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Resource Providers

Table 6: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Manufacturers (Suppliers)

Table 7: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Distributors And Channel Partners

Table 8: Global Human Metapneumovirus (hMPV) Therapeutics Market, Key Technologies & Future Trends

Table 9: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Trends

Table 10: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major End Users

Table 11: Global Human Metapneumovirus (hMPV) Therapeutics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Human Metapneumovirus (hMPV) Therapeutics Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Human Metapneumovirus (hMPV) Therapeutics Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Human Metapneumovirus (hMPV) Therapeutics Market - TAM, US$ Billion, 2025

Table 15: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Antipyretic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Decongestants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Cough Suppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Human Metapneumovirus (hMPV) Therapeutics Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Human Metapneumovirus (hMPV) Therapeutics Market - Company Scoring Matrix

Table 98: Pfizer Inc. Financial Performance

Table 99: Sanofi S.A Financial Performance

Table 100: AstraZeneca Plc Financial Performance

Table 101: Merck KGaA Financial Performance

Table 102: Moderna Inc Financial Performance

Table 103: Global Human Metapneumovirus (hMPV) Therapeutics Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Human Metapneumovirus (hMPV) Therapeutics Market, Competitive Dashboard

Table 105: Global Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Table 107: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Table 108: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By End-Use, 2025 – 2030

List Of Figures

Figure 1: Global Human Metapneumovirus (hMPV) Therapeutics Market, Overview Of Key Products - Product Examples

Figure 2: Global Human Metapneumovirus (hMPV) Therapeutics Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Human Metapneumovirus (hMPV) Therapeutics Market, Supply Chain Analysis

Figure 4: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Raw Material Providers

Figure 5: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Resource Providers

Figure 6: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Manufacturers (Suppliers)

Figure 7: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Distributors And Channel Partners

Figure 8: Global Human Metapneumovirus (hMPV) Therapeutics Market, Key Technologies & Future Trends

Figure 9: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major Trends

Figure 10: Global Human Metapneumovirus (hMPV) Therapeutics Market, Major End Users

Figure 11: Global Human Metapneumovirus (hMPV) Therapeutics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Human Metapneumovirus (hMPV) Therapeutics Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Human Metapneumovirus (hMPV) Therapeutics Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Human Metapneumovirus (hMPV) Therapeutics Market - TAM, US$ Billion, 2025

Figure 15: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Antipyretic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Decongestants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Cough Suppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Human Metapneumovirus (hMPV) Therapeutics Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Human Metapneumovirus (hMPV) Therapeutics Market - Company Scoring Matrix

Figure 98: Pfizer Inc. Financial Performance

Figure 99: Sanofi S.A Financial Performance

Figure 100: AstraZeneca Plc Financial Performance

Figure 101: Merck KGaA Financial Performance

Figure 102: Moderna Inc Financial Performance

Figure 103: Global Human Metapneumovirus (hMPV) Therapeutics Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Human Metapneumovirus (hMPV) Therapeutics Market, Competitive Dashboard

Figure 105: Global Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Figure 107: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Figure 108: Global, Human Metapneumovirus (hMPV) Therapeutics Market Size Gain ($ Billion), Segmentation By End-Use, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Viral Hepatitis Market Report 2026 - Global Outlook – By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types), By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis), By Treatment (...

Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2026 - Global Outlook – By Drug (Palivizumab, Ribavirin, Other Drugs), By Treatment (Immune Prophylaxis, Supportive Care, Antiviral Medications), By Dosage For...

Antivirals Market Report 2026 - Global Outlook – By Type (Branded, Generic), By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes),...

Herpes Simplex Virus Treatment Market Report 2026 - Global Outlook – By Type (Herpes Simplex Virus-1 Infection, Herpes Simplex Virus-2 Infection), By Drug Type (Acyclovir, Valacyclovir, Famciclovir, Other Drugs), By Rout...

Oncolytic Virus Therapy Market Report 2026 - Global Outlook – By Therapy Type (Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease V...

Viral Inactivation Market Report 2026 - Global Outlook – By Product (Kits And Reagents, Systems, Services), By Method (Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods), By Application (Vacci...

Infectious Disease Therapeutics Market Report 2026 - Global Outlook – By Type (Drugs, Vaccines), By Disease (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases), By End-User (Hospitals And Clinics, Retail Pharm...

Frequently Asked Questions

How big is the Human Metapneumovirus (hMPV) Therapeutics Market?

The Human Metapneumovirus (hMPV) Therapeutics market was valued at $0.7 billion in 2025, increased to $0.74 billion in 2026, and is projected to reach $0.94 billion by 2030.

What is the Human Metapneumovirus (hMPV) Therapeutics market growth?

The global Human Metapneumovirus (hMPV) Therapeutics market is expected to grow at a CAGR of 6.0% from 2026 to 2035 to reach $0.94 billion by 2035.

Who are the key players in Human Metapneumovirus (hMPV) Therapeutics market?

Some Key Players in the Human Metapneumovirus (hMPV) Therapeutics market Include, Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc. .

What is the anticipated growth trend for the Human Metapneumovirus (hMPV) Therapeutics market?

Major trend in this market includes: Development Of Targeted Antiviral Therapies In The Market. For further insights on this market. request a sample here

Which region has the most growth potential in the Human Metapneumovirus (hMPV) Therapeutics market?

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hmpv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.